Magrolimab Biosimilar – Anti-CD47 mAb – Research Grade

Description of Magrolimab Biosimilar - Anti-CD47 mAb - Research Grade

Introduction

Magrolimab Biosimilar, also known as Anti-CD47 monoclonal antibody (mAb), is a promising therapeutic agent that has shown potential in treating various types of cancers. This novel biosimilar is being developed by several pharmaceutical companies as a more affordable alternative to the original anti-CD47 mAb. In this article, we will explore the structure, activity, and potential applications of Magrolimab Biosimilar in cancer treatment.

Structure of Magrolimab Biosimilar

Magrolimab Biosimilar is a monoclonal antibody that specifically targets the CD47 protein. It is a humanized IgG4 antibody, meaning it is derived from human antibodies and has been modified to reduce its immunogenicity. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains, connected by disulfide bonds.

The variable region of Magrolimab Biosimilar is responsible for binding to CD47, while the constant region is responsible for activating the immune system. The binding site of the antibody is located on the Fc region, which is important for its therapeutic activity.

Activity of Magrolimab Biosimilar

The main mechanism of action of Magrolimab Biosimilar is through its binding to CD47. CD47 is a protein that is overexpressed on the surface of cancer cells, allowing them to evade detection and destruction by the immune system. By binding to CD47, Magrolimab Biosimilar blocks its interaction with the SIRPα receptor on macrophages, thus preventing the “don’t eat me” signal and allowing the immune system to recognize and eliminate cancer cells.

In addition to its direct anti-

cancer activity, Magrolimab Biosimilar also has immunomodulatory effects. It can activate macrophages, dendritic cells, and natural killer cells, leading to enhanced phagocytosis and production of pro-inflammatory cytokines. This further boosts the immune response against cancer cells.

Potential Applications of Magrolimab Biosimilar

Magrolimab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various types of cancers, including acute myeloid leukemia, non-Hodgkin’s lymphoma, and solid tumors such as ovarian, breast, and lung cancer.

One of the advantages of Magrolimab Biosimilar is its potential to be used in combination with other cancer therapies. It has been shown to synergize with chemotherapy, radiation therapy, and other immunotherapies, leading to improved efficacy and reduced toxicity.

Moreover, Magrolimab Biosimilar has the potential to be used in the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. By blocking the CD47-SIRPα interaction, it can prevent the destruction of healthy cells by the immune system.

Conclusion

Magrolimab Biosimilar is a promising anti-CD47 monoclonal antibody that has the potential to revolutionize cancer treatment. Its unique structure and mechanism of action make it a highly effective and versatile therapeutic agent. With ongoing research and clinical trials, Magrolimab Biosimilar has the potential to improve the lives of cancer patients and pave the way for more affordable and accessible treatments.

Keywords: Magrolimab Biosimilar, Anti-CD47 monoclonal antibody, cancer treatment, structure, activity, applications

SDS-PAGE for Magrolimab Biosimilar - Anti-CD47 mAb

Magrolimab Biosimilar - Anti-CD47 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Immobilized CD47 Recombinant Protein (Human) (cat. No.PX-P4083) at 0.5µg/mL (100µL/well) can bind to Magrolimab Biosimilar - Anti-CD47 mAb (cat. No.PX-TA1561) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450